Beta Drugs (NSE:BETA) Total Current Liabilities: ₹1,081 Mil (As of Mar. 2026)


NSE:BETA Beta Drugs Ltd NSE:BETA
88 GF Score
Price ₹2,153.40
GF Value ₹1,970.72
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Beta Drugs Total Current Liabilities?

Beta Drugs NSE:BETA +3.01% 88 Total Current Liabilities is ₹1,081 Mil as of Mar. 2026. GuruFocus rates NSE:BETA with a GF Score™ of 88/100 and a GF Value™ of ₹1,970.72 (Fairly Valued). The stock has 6 warning signs investors should review.

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Beta Drugs's total current liabilities for the quarter that ended in Mar. 2026 was ₹1,081

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Beta Drugs Total Current Liabilities Related Terms

Beta Drugs Total Current Liabilities Historical Data

* Premium members only.

The historical data trend for Beta Drugs's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beta Drugs Total Current Liabilities Chart

Beta Drugs Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 489.70 630.16 846.69 1,027.30 1,081.40

Beta Drugs Quarterly Data
Mar17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Dec24 Mar25 Sep25 Dec25 Mar26
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 1,027.30 1,143.57 0.00 1,081.40
NSE:BETA
88GF Score
Beta Drugs Ltd NSE:BETA
Total Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Beta Drugs Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Beta Drugs's Total Current Liabilities for the fiscal year that ended in Mar. 2026 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=806.279+144.821
+Other Current Liabilities+Current Deferred Liabilities
=130.304+0
=1,081

Beta Drugs's Total Current Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=806.279+144.821
+Other Current Liabilities+Current Deferred Liabilities
=130.304+0
=1,081

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

What does a Total Current Liabilities of ₹1,081 Mil mean?
Beta Drugs (NSE:BETA) has a Total Current Liabilities of ₹1,081 Mil as of Mar. 2026. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Beta Drugs and its competitors.
Is Beta Drugs' Total Current Liabilities too high?
Beta Drugs' current Total Current Liabilities is ₹1,081 Mil. Overall, Beta Drugs has a GF Score™ of 88/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Beta Drugs' Total Current Liabilities compare to ZTS and UTHR?
Beta Drugs' Total Current Liabilities of ₹1,081 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Liabilities for a Drug Manufacturers company?
A good Total Current Liabilities depends on the Drug Manufacturers industry context. However, Total Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Liabilities mean?
A high Total Current Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Beta Drugs and its competitors. Beta Drugs's current Total Current Liabilities is ₹1,081 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beta Drugs stock overvalued right now?
Based on GuruFocus' analysis, Beta Drugs (NSE:BETA) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,970.72, compared to a current price of ₹2,153.40 — trading 9.3% above its estimated fair value. The current Total Current Liabilities is ₹1,081 Mil. Beta Drugs' overall GF Score™ is 88/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Liabilities calculated?
Total Current Liabilities is calculated from a company's financial statements. For Beta Drugs (NSE:BETA), the current Total Current Liabilities is ₹1,081 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Beta Drugs (NSE:BETA) Overvalued in 2026?

Based on GuruFocus' analysis, Beta Drugs stock appears to be overvalued. The current stock price of ₹2,153.40 is trading 9.3% above its estimated GF Value™ of ₹1,970.72. GuruFocus considers Beta Drugs to be Fairly Valued.

Key valuation signals for NSE:BETA:

  • Total Current Liabilities: ₹1,081 Mil
  • GF Value™: ₹1,970.72 vs. price of ₹2,153.40 (9.3% above fair value)
  • GF Score™: 88/100 with 6 warning signs

No single metric tells the full story. See the NSE:BETA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Beta Drugs Business Description

Address SCO-184, First Floor, Sector-5, Panchkula, HR, IND, 134114
Beta Drugs Ltd operates in the pharmaceutical industry. The company manufactures and sells Oncology products in the form of tablets, capsules, oral formulations, and injections. It sells the products in India and also exports them to other countries, of which key revenue is derived from the sales made in India.
88GF Score

Get the complete analysis for NSE:BETA

Total Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,153.40
Price
₹1,970.72
GF Value